June 1, 2022 | Targeted Therapies in Oncology

Second CAR T Infusion Could Lead to New Response in B-ALL

June 18, 2022

Clinical Articles

Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.

Positive Outcomes of Novel Cellular Therapies Are Seen in Long Relapse, DLBCL

June 17, 2022

Clinical Articles

Patients with relapsed/refractory diffuse large B-cell lymphoma who benefit most from novel therapies vs patients who would likely do well with standard treatment were identified among all curatively treated patients in Sweden from 2007 to 2014.

Minimal Difference in Efficacy Shown for Immunotherapy Combos in Poor-Performance Metastatic RCC

June 17, 2022

Clinical Articles

Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.

Triplet Combination Data Add Evidence to Clinical Activity in aRCC

June 16, 2022

Clinical Articles

Data regarding the triplet combination of nivolumab, ipilimumab, and cabozantinib show clinical activity across multiple tumor types, giving a preview of future outcomes in patients with untreated, advanced renal cell carcinoma.

Learning to Beat the Clock—Stressing the Timing of Immunotherapy

June 15, 2022

Clinical Articles

Most studies of how timing affects immunotherapy efficacy have defined “timing” relative to other treatments, but some research has investigated the impact of giving patients immunotherapy at different times of day.